An act relating to captive insurance companies
This bill makes several targeted changes to Vermont’s captive insurance statutes. First, it amends the rules governing risk retention groups by continuing a prohibition on loans to, or investments in, members or affiliates of members, while exempting preexisting transactions already in place before January 1, 2026. It also revises reporting requirements for captive insurance companies and risk retention groups, clarifying annual and quarterly filing obligations, acceptable accounting methods, and the Commissioner’s authority to prescribe report forms and additional filing requirements.
The bill also adds a new requirement for protected cells: within 30 days after beginning business, each protected cell must file a sworn statement with the Commissioner certifying that it had the required funding, including any required collateral, before commencing operations. The statement must be signed by specified officers or authorized individuals depending on the protected cell’s legal form. The act takes effect July 1, 2026.
The bill primarily affects Vermont’s captive insurance regulatory framework in Title 8, including provisions governing legal investments, annual and quarterly reporting, and protected cell operations. It gives the Insurance Commissioner continued and clarified oversight authority over reporting formats, accounting standards, electronic filing with the NAIC, and additional filing requirements for risk retention groups. It also imposes a new post-commencement certification requirement on protected cells, which may increase compliance obligations for captive insurers, sponsored captives, and related entities.
Based on the bill text and the absence of recorded committee debate or votes in the provided materials, the overall sentiment appears neutral and administrative rather than controversial. The measure reads as a technical regulatory update intended to clarify filing rules, preserve existing investment restrictions, and strengthen documentation around protected cell capitalization. The governor signed the bill, suggesting it was acceptable to the executive branch and likely viewed as a routine insurance-oversight measure.
No specific points of contention are reflected in the provided transcripts or voting history, so there is no documented opposition or amendment dispute to identify. The most likely areas of policy sensitivity are the continued restriction on risk retention group investments in members or affiliates, the Commissioner’s authority to require additional filings, and the new sworn certification requirement for protected cells. However, the available record does not show any organized disagreement over those provisions.